215 related articles for article (PubMed ID: 10896992)
1. [Viral safety: European and French directives].
Rossi F; Legras JF
Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S55-61. PubMed ID: 10896992
[TBL] [Abstract][Full Text] [Related]
2. Virus validation procedures: practical aspects.
Minor PD
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S10-2. PubMed ID: 7495959
[TBL] [Abstract][Full Text] [Related]
3. Opinion of the EMEA on the potential risk associated with medicinal products in relation to bovine spongiform encephalopathy (BSE) (16 April 1996) and report from the Committee for Proprietary Medicinal Products (CPMP) on the 'Note for Guidance on minimizing the risk of transmitting animal spongiform encephalopathies via medicinal products' (15 April 1997).
Adverse Drug React Toxicol Rev; 1997 Jun; 16(2):113-21. PubMed ID: 9359933
[No Abstract] [Full Text] [Related]
4. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
[TBL] [Abstract][Full Text] [Related]
5. European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements.
Robertson JS; Cichutek K
Dev Biol (Basel); 2000; 104():53-6. PubMed ID: 11713824
[TBL] [Abstract][Full Text] [Related]
6. EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
Biologicals; 1991 Jul; 19(3):247-51. PubMed ID: 1954007
[No Abstract] [Full Text] [Related]
7. Current strategies to prevent transmission of prions by human plasma derivatives.
Burnouf T; Padilla A
Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
[TBL] [Abstract][Full Text] [Related]
8. Note for guidance. Guidelines for minimizing the risk of transmitting agents causing spongiform encephalopathy via medicinal products. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
Biologicals; 1992 Jun; 20(2):155-8. PubMed ID: 1389111
[No Abstract] [Full Text] [Related]
9. Consensus statement on the bio-safety of urinary-derived gonadotrophins with respect to Creutzfeldt-Jakob disease.
Balen AH; Lumholtz IB
Hum Reprod; 2005 Nov; 20(11):2994-9. PubMed ID: 16055457
[TBL] [Abstract][Full Text] [Related]
10. Selection of spiking materials for studies on the clearance of agents of transmissible spongiform encephalopathy during plasma fractionation.
Foster PR
Biologicals; 2008 Mar; 36(2):142-3. PubMed ID: 17400473
[TBL] [Abstract][Full Text] [Related]
11. Avoiding viral contamination in biotechnological and pharmaceutical processes.
Henzler HJ; Kaiser K
Nat Biotechnol; 1998 Nov; 16(11):1077-9. PubMed ID: 9831040
[No Abstract] [Full Text] [Related]
12. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal.
Flan B; Arrabal S
Transfus Clin Biol; 2007 May; 14(1):51-62. PubMed ID: 17540602
[TBL] [Abstract][Full Text] [Related]
13. Viral safety of a new highly purified factor VIII (OCTATE).
Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
[TBL] [Abstract][Full Text] [Related]
14. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
15. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
Celis P; Silvester G
Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
[TBL] [Abstract][Full Text] [Related]
16. Viral safety in homoeopathic medicinal products.
Schultz N; Franck-Karl G; Schilk J; Rose N
Pharmeur Bio Sci Notes; 2011 Jun; 2011(1):55-65. PubMed ID: 21619856
[TBL] [Abstract][Full Text] [Related]
17. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
Ludlam CA; Turner ML
Br J Haematol; 2006 Jan; 132(1):13-24. PubMed ID: 16371015
[TBL] [Abstract][Full Text] [Related]
18. CJD PrPsc removal by nanofiltration process: application to a therapeutic immunoglobulin solution (Lymphoglobuline).
Truchot L; Arnaud T; Bloy C; Perret-Liaudet A
Biologicals; 2006 Sep; 34(3):227-31. PubMed ID: 16490361
[TBL] [Abstract][Full Text] [Related]
19. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
20. Tissue safety in view of CJD and variant CJD.
Pauli G
Cell Tissue Bank; 2005; 6(3):191-200. PubMed ID: 16151959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
